Dyne Therapeutics Announces Upcoming Investor Conferences
Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage biotechnology company, has a clear mission: to deliver functional improvement for individuals affected by genetically driven neuromuscular diseases. The company recently shared its schedule for several upcoming investor conferences that are set to showcase its innovative approaches and programs.
Key Conferences to Attend
The management of Dyne Therapeutics will be presenting at an array of notable investor conferences this November and December. These events are crucial for the company not only to gain visibility but to also share its progress and insights within the industry.
Guggenheim Healthcare Innovation Conference
The first prominent event on their agenda is the Guggenheim 2nd Annual Healthcare Innovation Conference. The company will participate in a fireside chat on Monday, November 10, 2025. This event will take place at 10:00 a.m. ET and serves as an excellent platform for Dyne to highlight its advancements in therapeutic solutions.
Stifel Healthcare Conference
Following this, Dyne will also be at the Stifel 2025 Healthcare Conference, scheduled for Tuesday, November 11, 2025, at 9:20 a.m. ET. Here, Dyne aims to reach a broader audience of investors and stakeholders interested in innovative healthcare solutions.
Jefferies Global Healthcare Conference
On Monday, November 17, 2025, Dyne will take the stage at the Jefferies Global Healthcare Conference, with its presentation set for 3:00 p.m. GMT (10:00 a.m. ET). The company will utilize this opportunity to delve deeper into their clinical programs and the scientific rationale behind their strategies.
Evercore Healthcare Conference
Finally, the company will culminate its conference schedule with a presentation at the 8th Annual Evercore Healthcare Conference on Tuesday, December 2, 2025, at 9:35 a.m. ET. This event, held in Coral Gables, FL, is anticipated to further solidify Dyne's presence in the healthcare sector.
Webcast Availability
For those unable to attend the live presentations, Dyne Therapeutics will provide a live webcast of each event. Interested parties can access these webcasts through the Investors & Media section of the Dyne website, ensuring that all stakeholders have the opportunity to stay informed regarding the company’s initiatives. Moreover, replays of the presentations will be available for a period of 90 days following the events.
About Dyne Therapeutics
Dyne Therapeutics is on a path to transform lives through its development of therapies aimed at addressing the core challenges faced by individuals with genetically driven neuromuscular diseases. Their clinical programs focus on conditions such as myotonic dystrophy type 1 (DM1) and Duchenne muscular dystrophy (DMD), while also working on preclinical initiatives for facioscapulohumeral muscular dystrophy (FSHD) and Pompe disease. At the heart of Dyne's mission is the commitment to enhancing the lives of individuals, families, and communities impacted by these debilitating conditions. To learn more about their work and advancements, please visit their [website](https://www.dyne-tx.com).
Frequently Asked Questions
What is the main focus of Dyne Therapeutics?
Dyne Therapeutics focuses on developing therapies for genetically driven neuromuscular diseases to improve patients' quality of life.
When will Dyne Therapeutics be presenting at the investor conferences?
Dyne Therapeutics is set to present at several conferences throughout November and December 2025.
Where can I find the webcasts for their presentations?
Live webcasts and recordings of the presentations will be available on the Investors & Media section of Dyne's website.
What diseases are Dyne Therapeutics currently targeting?
Dyne Therapeutics is currently targeting myotonic dystrophy type 1, Duchenne muscular dystrophy, facioscapulohumeral muscular dystrophy, and Pompe disease.
How can I contact Dyne Therapeutics for more information?
For inquiries, you can reach out to Dyne's Investor Relations at ir@dyne-tx.com or call 781-317-0353.